Comparison Of Anti-seizure Affect Carbamazepin And Valproat Sodium In Treatment Seizure

Comparison Of Anti-seizure Affect Carbamazepine And Valproate Sodium With Monotherapy In Treatment Seizure In Adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050717611N1

Enrollment

126

Registered

2014-05-19

Start date

2014-05-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: EPILEPSY. Condition 2: Seizure. Status epilepticus epilepsy

Interventions

Intervention 1: Group That Treat With Valproate Sodium, Tablet Valproate Sodium, 200 Mg, Bid, Oral, For 5 month. Intervention 2: Group That Treat Whith Carbamazepin, Carbamazepin, Tab 200 Mg ,Bid, For

Treatment - Drugs

Group That Treat With Valproate Sodium, Tablet Valproate Sodium, 200 Mg, Bid, Oral, For 5 month

Group That Treat Whith Carbamazepin, Carbamazepin, Tab 200 Mg ,Bid, For 5month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria:People with 18 years; who that not treatment with anti seizure drugs; dont have history off cva. Exclusion criteria:People with-18 years; pegnancy; cva and cerebral tumor; hysterical seizure or metabolic seizure; who that dont have change in eeg; who that dont have adhesion

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Outbreak Of Seizure. Timepoint: Start Of Treatment, Secondary week, First Month,Third Month, Fifth Month. Method of measurement: Clinical Examination, Eeg.	—

Secondary

Measure	Time frame
Overweight. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Vomiting. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Epidermal side affect. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Headache. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Diplopia. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Vertigo. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.	—

Measure

Time frame

Overweight. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Vomiting. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Epidermal side affect. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Headache. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Diplopia. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Vertigo. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRohollah Eshghi Kejghaneh

Vali Asr Hospital

Rooheeshghi@gmail.com, Rooheeshghi@bums.ac.ir+98 53 2824 2089

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026